Items where authors include "Pedroncelli, A.M."

Article

Fleseriu, M., Pivonello, R., Newell-Price, J. et al. (10 more authors) (2025) Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies. Pituitary, 28. 22. ISSN 1386-341X

Newell-Price, J. orcid.org/0000-0002-0835-5493, Fleseriu, M. orcid.org/0000-0001-9284-6289, Pivonello, R. orcid.org/0000-0002-9632-1348 et al. (8 more authors) (2024) Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol. Journal of the Endocrine Society, 9 (1). bvae201. ISSN 2472-1972

Pivonello, R. orcid.org/0000-0002-9632-1348, Fleseriu, M. orcid.org/0000-0001-9284-6289, Newell-Price, J. orcid.org/0000-0002-0835-5493 et al. (9 more authors) (2024) Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the phase III LINC 3 trial in Cushing's disease. Journal of Endocrinological Investigation, 47 (10). pp. 2437-2448. ISSN 0391-4097

Fleseriu, M., Newell-Price, J., Pivonello, R. et al. (12 more authors) (2022) Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension. European Journal of Endocrinology, 187 (4). pp. 531-541. ISSN 0804-4643

Pivonello, R., Fleseriu, M., Newell-Price, J. et al. (14 more authors) (2020) Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a doubleblind, randomised withdrawal phase. The Lancet Diabetes & Endocrinology, 8 (9). pp. 748-761. ISSN 2213-8587

Findling, J.W., Fleseriu, M., Newell-Price, J. et al. (5 more authors) (2016) Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study. Endocrine, 54 (2). pp. 516-523. ISSN 1355-008X

Proceedings Paper

Fleseriu, M., Pivonello, R., Newell-Price, J. et al. (10 more authors) (2024) 6907 Continued improvements in hypertension and diabetes during long-term osilodrostat therapy in patients with Cushing’s disease: a pooled analysis from the phase III LINC 3 and LINC 4 studies. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .